Oncology
ITM Oncologics GmbH is focused on unresectable locally advanced and metastatic solid tumors, with activity spanning clear cell renal cell carcinoma, pancreatic ductal adenocarcinoma, colorectal cancer, urothelial carcinoma, head and neck cancer, triple negative breast cancer, and squamous non-small cell lung cancer.
- Clear cell renal cell carcinoma
- Pancreatic ductal adenocarcinoma
- Colorectal cancer
- Urothelial carcinoma
- Triple negative breast cancer
The sponsor’s research interest includes tumor types with limited local treatment options and advanced disease burden across genitourinary, gastrointestinal, thoracic, and breast cancer settings.
Radiopharmaceutical Therapy
The clinical program centers on radioligand therapy using lutetium-177-based treatment approaches and paired gallium-68 imaging agents, reflecting interest in both therapeutic and diagnostic applications of targeted radionuclide medicine.
- [177Lu]Lu-DPI-4452
- [68Ga]Ga-DPI-4452
- Targeted radionuclide therapy
- Theranostic imaging
This area links molecular targeting with internal radiation delivery in solid tumors.
Molecular Imaging
The sponsor is active in PET/CT imaging and tumor uptake assessment, with a strong emphasis on visualizing disease distribution and tracer localization across multiple tumor types.
- PET/CT
- Tracer uptake
- Diagnostic concordance
- Histopathology correlation
Research interest also extends to indeterminate renal mass evaluation, where imaging performance is compared with tissue findings.
Genitourinary Oncology
A notable portion of the sponsor’s clinical activity is directed toward genitourinary cancers, especially urothelial carcinoma, clear cell renal cell carcinoma, and indeterminate renal mass.
- Urothelial carcinoma
- Renal cell carcinoma
- Renal mass characterization
- Urinary tract malignancies
These areas indicate sustained interest in imaging and treatment strategies for kidney and urinary tract tumors.
Advanced Solid Tumor Care
The sponsor’s research landscape also includes head and neck cancer, triple negative breast cancer, and squamous non-small cell lung cancer, broadening its therapeutic reach across aggressive epithelial malignancies.
- Head and neck cancer
- Squamous non-small cell lung cancer
- Triple negative breast cancer
- Advanced epithelial tumors
These studies align with interest in difficult-to-treat solid tumors where targeted imaging and radionuclide-based approaches are being explored.
